A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-06

Study Completion Date

2023-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease

NCT06491342

Fatty Liver, Nonalcoholic

COMPLETED NA

Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials

NCT06873165

Metabolic Dysfunction-Associated Steatotic Liver Disease

RECRUITING NA

Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects

NCT05930093

NAFLD

RECRUITING NA

Probiotics in NASH Patients - PROBILIVER TRIAL

NCT03467282

Non-Alcoholic Fatty Liver Disease

UNKNOWN NA

Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy

NCT06152991

Non-Alcoholic Fatty Liver Disease

ENROLLING_BY_INVITATION PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, Parallel Group, Placebo Controlled Trial

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Sequentially numbered, sealed, opaque envelopes

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MXP22 (Probiotic and antioxidant capsule)

Dose : NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Group Type EXPERIMENTAL

MXP22 (Probiotic and antioxidant capsule)

Intervention Type OTHER

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Placebo (Microcrystalline Cellulose )

Dose : NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once dailybafter lunch for 120 days

Group Type PLACEBO_COMPARATOR

Placebo (Microcrystalline Cellulose)

Intervention Type OTHER

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MXP22 (Probiotic and antioxidant capsule)

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Intervention Type OTHER

Placebo (Microcrystalline Cellulose)

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult men and women aged more than equal to 30 and less than or equal to 60 years, diagnosed with NAFLD within last 2 years.
2. CAP scores more than equal to 248 and less than or equal to 270 dB/m indicating steatosis grade I/ II.
3. Non-alcoholics (little or no consumption of alcohol).
4. Willing to participate in the study with a signed and dated written consent.
5. Overweight and obese participant with BMI more than or equal to 25 kg/m2.
6. Having at least 3 of the following five metabolic risk factors:

i Waist circumference: Men: more than or equal to102 cm (40.15 inches); Women more than or equal to 88 cm (34.65 inches).

ii Triglycerides \>150 mg/dL. iii Blood pressure more than or equal to 130 mm Hg (systolic, SBP) and/or more than or equal to 85 mm Hg (diastolic, DBP).

iv Fasting blood glucose more than or equal to 100 mg/ dl. v Low HDL level: Men: \< 40 mg/dL; Women: \< 50 mg/dL.

Exclusion Criteria

1. Treatment of NAFLD for at least 3 months prior to the screening.
2. History of decompensated liver disease (ascites, encephalopathy, variceal bleeding).
3. Participants with liver cirrhosis, any concomitant liver disease.
4. Participants with systemic inflammatory disease or autoimmune disorders.
5. Participants with blood pressure Less than or equal to 160 mm Hg (systolic, SBP) and/or less than or equal to 95 mm Hg (diastolic, DBP).
6. Participants with Fasting blood glucose Less than or equal to 140 mg/ dl.
7. Participants with cardiopulmonary disease.
8. Heavy alcohol drinkers defined as follows:

i For men, consuming more than 4 drinks on any day or more than 14 drinks/week ii For women, consuming more than 3 drinks on any day or more than 7 drinks/week
9. Participants with liver cancer - primary hepatocellular carcinoma or liver metastasis.
10. Participants with other systemic disorders of the heart, lungs, blood, and endocrine system, including thyroid dysfunction and Type I diabetes mellitus.
11. Histologic evidence of NASH with fibrosis stage (METAVIR score) F1 or F4.
12. Individuals with Inflammatory bowel diseases.
13. Use of medications containing systemic steroids, methotrexate corticosteroids, amiodarone, tamoxifen, valproate, vitamin E, omega-3, Anti-retroviral agents; 1 month prior to screening.
14. Intake of probiotics (lactic acid bacteria, etc.), prebiotics (dietary fiber, fructooligo saccharide, etc.), new biotics, fermented milk and proton pump inhibitor within one month before screening or during the study period.
15. Participants who have hypersensitivity to the test drug/ placebo or components contained in the test drug/placebo or have severe allergic reactions.
16. Females who are breast-feeding, lactating, pregnant or intending to become pregnant.
17. Regular use of a probiotic or prebiotic supplement within 3 months prior to screening.
18. Antibiotic use within 3 weeks prior to screening.

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No